A qualidade das pesquisas sobre judicialização e sua influência nas políticas públicas de acesso aos medicamentos no Brasil: uma revisão sistemática

Lyra, Pollyanna Farias Castro Pereira de; Araújo, Dyego Carlos Souza Anacleto de; Santos Júnior, Genival Araújo dos; Sodré-Alves, Bárbara Manuella Cardoso; Jesus, Elisdete Maria Santos de; Lyra Jr., Divaldo Pereira de; Quintans Jr., Lucindo José

doi:10.1590/1413-812320212611.29142020

Acessibilidade / Reportar erro

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

ARTICLE • Ciênc. saúde coletiva 26 (11) • Nov 2021 • https://doi.org/10.1590/1413-812320212611.29142020 copiar

A qualidade das pesquisas sobre judicialização e sua influência nas políticas públicas de acesso aos medicamentos no Brasil: uma revisão sistemática

Autoria SCIMAGO INSTITUTIONS RANKINGS

Resumo

Pacientes sem acesso a medicamentos geralmente recorrem ao sistema judicial. No entanto, nenhuma revisão sistemática discutiu a qualidade dos estudos e os fatores que podem influenciar o acesso aos medicamentos pela judicialização. Este estudo teve como objetivo caracterizar a qualidade da pesquisa sobre acesso a medicamentos judicializados e sua influência nas políticas públicas no Brasil. Foi realizada uma pesquisa nas bases de dados LILACS, PubMed/Medline, Scopus e Web of Science usando os termos “judicialization” e “medication”. Dois revisores identificaram artigos que atendiam aos critérios de inclusão. Apenas estudos escritos em inglês, português ou espanhol publicados de 1990 a 2018 foram incluídos. A seleção do estudo resultou em uma amostra final de 45 artigos. O desenho descritivo retrospectivo foi o método mais comum, com base em relatos e ações judiciais. Um alto nível de heterogeneidade entre os estudos impediu a comparação e a geração de evidências capazes de apoiar as decisões dos juízes com base em critérios técnico-científicos. Esta revisão mostrou que os estudos eram heterogêneos e apresentavam baixa qualidade metodológica. Além disso, não propuseram soluções viáveis para gerentes e formuladores de saúde enfrentarem o problema.

Palavras-chave:
Direito à saúde; Medicamentos; Decisões judiciais; Acesso a medicamentos; Custos com medicamentos

LILACS = 146
(“Judicial Role” OR “Judicial Roles” OR “Role, Judicial” OR “Roles, Judicial” OR “Judicial Action” OR “Action, Judicial” OR “Actions, Judicial” OR “Judicial Actions” OR “Court Action” OR “Action, Court” OR “Actions, Court” OR “Court Actions” OR “Judicial Consent” OR “Consent, Judicial” OR “Judicial Bypass” OR “Bypass, Judicial” OR “judicial decisions” OR “judicial decision” OR “judicialization” OR “judicializations”) AND (“Brazil”) AND (“pharmaceutical preparations” OR “pharmaceutical preparation” OR “Preparations, Pharmaceutical” OR “Pharmaceutic Preparations” OR “Preparations, Pharmaceutic” OR “Pharmaceutical Products” OR “Products, Pharmaceutical” OR “Pharmaceuticals” OR “Pharmaceutical” OR “Drugs” OR “Drug” OR “Medicine” OR “Medicines”)
PUBMED = 54
((“Pharmaceutical Preparations”[Mesh]) OR (((((((((((((“pharmaceutical preparations”) OR (“pharmaceutical preparation”)) OR (“Preparations, Pharmaceutical”)) OR (“Pharmaceutic Preparations”)) OR (“Preparations, Pharmaceutic”)) OR (“Pharmaceutical Products”)) OR (“Products, Pharmaceutical”)) OR (“Pharmaceuticals”)) OR (“Pharmaceutical”)) OR (“Drugs”)) OR (“Drug”)) OR (“Medicine”)) OR (“Medicines”))) AND ((“Judicial Role”[Mesh]) OR ((((((((((((((((((((“Judicial Role”) OR (“Judicial Roles”)) OR (“Role, Judicial”)) OR (“Roles, Judicial”)) OR (“Judicial Action”)) OR (“Action, Judicial”)) OR (“Actions, Judicial”)) OR (“Judicial Actions”)) OR (“Court Action”)) OR (“Action, Court”)) OR (“Actions, Court”)) OR (“Court Actions”)) OR (“Judicial Consent”)) OR (“Consent, Judicial”)) OR (“Judicial Bypass”)) OR (“Bypass, Judicial”)) OR (“judicial decisions”)) OR (“judicial decision”)) OR (“judicialization”)) OR (“judicializations”))) AND (Brazil)
SCOPUS = 472
( ALL ( “Brazil” ) ) AND ( ( ALL ( “Judicial Role” ) OR ALL ( “Judicial Roles” ) OR ALL ( “Role, Judicial” ) OR ALL ( “Roles, Judicial” ) OR ALL ( “Judicial Action” ) OR ALL ( “Action, Judicial” ) OR ALL ( “Actions, Judicial” ) OR ALL ( “Judicial Actions” ) OR ALL ( “Court Action” ) OR ALL ( “Action, Court” ) OR ALL ( “Actions, Court” ) OR ALL ( “Court Actions” ) OR ALL ( “Judicial Consent” ) OR ALL ( “Consent, Judicial” ) OR ALL ( “Judicial Bypass” ) OR ALL ( “Bypass, Judicial” ) OR ALL ( “judicial decisions” ) OR ALL ( “judicial decision” ) OR ALL ( “judicialization” ) OR ALL ( “judicializations” ) ) ) AND ( ( ALL ( “pharmaceutical preparations” ) OR ALL ( “pharmaceutical preparation” ) OR ALL ( “Preparations, Pharmaceutical” ) OR ALL ( “Pharmaceutic Preparations” ) OR ALL ( “Preparations, Pharmaceutic” ) OR ALL ( “Pharmaceutical Products” ) OR ALL ( “Products, Pharmaceutical” ) OR ALL ( “Pharmaceuticals” ) OR ALL ( “Pharmaceutical” ) OR ALL ( “Drugs” ) OR ALL ( “Drug” ) OR ALL ( “Medicine” ) OR ALL ( “Medicines” ) ) )
WEB OF SCIENCE = 76
(TS=(“Pharmaceutical Preparation”) OR TS=(“pharmaceutical preparations”) OR TS=(“Preparations, Pharmaceutical”) OR TS=(“Pharmaceutic Preparations”) OR TS=(“Preparations, Pharmaceutic”) OR TS=(“Pharmaceutical Products”) OR TS=(“Products, Pharmaceutical”) OR TS=(“Pharmaceuticals”) OR TS=(“Pharmaceutical”) OR TS=(“Drugs”) OR TS=(“Drug”) OR TS=(“Medicine”) OR TS=(“Medicines”)) AND (TS=(“Judicial Role”) OR TS=(“Judicial Roles”) OR TS=(“Role, Judicial”) OR TS=(“Roles, Judicial”) OR TS=(“Judicial Action”) OR TS=(“Action, Judicial”) OR TS=(“Actions, Judicial”) OR TS=(“Judicial Actions”) OR TS=(“Court Action”) OR TS=(“Action, Court”) OR TS=(“Actions, Court”) OR TS=(“Court Actions”) OR TS=(“Judicial Consent”) OR TS=(“Consent, Judicial”) OR TS=(“Judicial Bypass”) OR TS=(“Bypass, Judicial”) OR TS=(“judicial decisions”) OR TS=(“judicial decision”) OR TS=(“judicialization”) OR TS=(“judicializations”)) AND (Brazil)
EMBASE = 70
(‘judicial role’ OR ‘judicial roles’ OR ‘role, judicial’ OR ‘roles, judicial’ OR ‘judicial action’ OR ‘action, judicial’ OR ‘actions, judicial’ OR ‘judicial actions’ OR ‘court action’ OR ‘action, court’ OR ‘actions, court’ OR ‘court actions’ OR ‘judicial consent’ OR ‘consent, judicial’ OR ‘judicial bypass’ OR ‘bypass, judicial’ OR ‘judicial decisions’ OR ‘judicial decision’ OR ‘judicialization’ OR ‘judicializations’) AND (‘pharmaceutical preparations’ OR ‘pharmaceutical preparation’ OR ‘preparations, pharmaceutical’ OR ‘pharmaceutic preparations’ OR ‘preparations, pharmaceutic’ OR ‘pharmaceutical products’ OR ‘products, pharmaceutical’ OR ‘pharmaceuticals’ OR ‘pharmaceutical’ OR ‘drugs’ OR ‘drug’ OR medicine’ OR ‘medicines’) AND (‘Brazil’)

	Item N^o	Recommendation	n (%)
Title and abstract	1	Indicate the study’s design with a commonly used term in the title or the abstract. Provide in the abstract an informative and balanced summary of what was done and what was found	44 (97,8)
Introduction
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	42 (93,3)
Objectives	3	State specific objectives	8 (17,8)
Objectives	3	Prespecified hypotheses	3 (6,7)
Methods
Study design	4	Present key elements of study design early in the paper	37 (82,2)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	42 (93,3)
Participants	6	(a) Cross-sectional study-Give the eligibility criteria, and the sources and methods of selection of participants	17 (37,8)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	33 (73,3)
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	41 (91,1)
Bias	9	Describe any efforts to address potential sources of bias	7 (15,6)
Study size	10	Explain how the study size was arrived at	31 (68,9)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	38 (84,4)
Statistical methods	12	Describe all statistical methods, including those used to control for confounding. Explain how missing data were addressed. Cross-sectional study-If applicable, describe analytical methods taking account of sampling strategy	23 (51,1)
Results
Participants	13	Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	17 (37,8)
Descriptive data	14	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	43 (95,6)
Outcome data	15	Report numbers of outcome events or summary measures	31 (68,9)
Main results	16	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included. Report category boundaries when continuous variables were categorized. If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.	44 (97,8)
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses	8 (17,8)
Discussion
Key results	18	Summarise key results with reference to study objectives	44 (97,8)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20 (44,4)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	42 (93,3)
Generalisability	21	Discuss the generalisability (external validity) of the study results	9 (29,0)
Other information
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16 (35,6)

ABRASCO - Associação Brasileira de Saúde Coletiva Av. Brasil, 4036 - sala 700 Manguinhos, 21040-361 Rio de Janeiro RJ - Brazil, Tel.: +55 21 3882-9153 / 3882-9151 - Rio de Janeiro - RJ - Brazil
E-mail: cienciasaudecoletiva@fiocruz.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Collaborations

PFCP Lyra, DP Lyra Jr. and LJ Quintans Jr. were responsible for the concept of the theme. PFCP Lyra, DCSA Araújo and GA Santos Jr collected the material. PFCP Lyra, EMS Jesus, BMCS Alves, DCSA Araújo and DP Lyra Jr. analyzed the material found. PFCP Lyra, BMCS Alves, EMS Jesus, DCSA Araújo and GA Santos Jr. wrote the first draft. PFCP Lyra, DP Lyra Jr. and LJ Quintans Jr. conducted critical reviews. All authors have approved the final version of this manuscript.